Our Governance
Our Governance
The overarching role of the committee is to:
Specifically excluded from the role of the committee is the occupational health and safety of employees. Health matters are included in the role of the HR & REMCO. In addition, GSEC receives a report on the safety aspects.
* Co-opted members of the committee
** from 27 November 2024
The committee's primary focus remained to ensure the safety of donors, recipients and employees while SANBS implemented the final year of the iHEALTh strategy and reinforced its role as a fundamental part of the healthcare ecosystem. Key issues addressed include:
The Platelet Strategy aims to ensure a sufficient platelet supply through increased donor recruitment, optimised collections, and clinician education on this scarce resource. Q4 saw the highest apheresis platelet collections in over five years, enabling the team to meet the demand during a particularly challenging quarter. Ongoing refinement of the Platelet Strategy 3.0 will be integrated into routine operations, with careful monitoring of product availability and expirations.
Noted that SANBS continues to be actively involved in and leads PBM initiatives to enhance the appropriate use of blood and blood products, thus optimising patient outcomes.
Noted that the project has transitioned to full maintenance mode, following resolution of previously outstanding critical tickets. The remaining issues are managed as new requests.
All SANBS collection sites and core laboratories hold ISO 15189 accreditation. Compromised safety and quality of blood products risks remains well managed, backed by:
Harmonisation of standards: The overall quality management system at SANBS is robust and effectively managed, reflecting management's commitment to quality and continuous improvement. SANBS received ISO 9001 accreditation and has successfully maintained its ISO 20387 accreditation and has achieved positive outcomes for ISO 17043 and ISO 13485, confirming its dedication to high standards in quality management.
Product Compliance: Monitoring and reporting product compliance to standards has been challenging since the eProgesa launch. A cross-functional team from ICT Business Applications and Business Intelligence is working to address these issues and identify solutions, with corrections set to be implemented at the start of FY26. Overall product compliance was maintained despite these challenges
Maintained the Joint Accreditation Committee ISCT-EBMT (JACIE) (cellular therapies) and the European Federation for Immunogenetics (EFI) (tissue immunology). With these achievements, SANBS realised the goal of having all areas of the business independently accredited to the relevant international standards
Reviewed and approved SANBS’ medical malpractice insurance
Closely monitored potential medico-legal cases.